Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:28:25.868Z.
Calculation as of: 2026-10-06T17:28:25.868Z.
Quote observation: 2026-10-06T17:25:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 970d877bc7db717cbed859036c212f4e9de57f4ce891843b12d0c27006da4837
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$940.00M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$932.15M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$914.98M
EV/EBITDA Ratio
12.55x
TTM Avg
10.56x
3Y Avg
12.81x
5Y Avg
13.69x
Market Cap
$971.27M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$972.72M
EV/EBITDA Ratio
11.38x
TTM Avg
10.94x
3Y Avg
46.55x
5Y Avg
35.86x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $940.00M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $942.80M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $945.74M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $931.88M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $932.15M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $963.47M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.98M | 12.55x | 10.56x | 12.81x | 13.69x |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $971.27M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $972.72M | 11.38x | 10.94x | 46.55x | 35.86x |
| MeiraGTx Holdings plc (MGTX)vs › | $977.03M | 4.82x | 6.06x | 6.06x | 6.06x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
